Xilio Therapeutics, Inc. received an amended Schedule 13G showing several Frazier Life Sciences funds as significant shareholders of its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 4,676,472 shares, representing 6.7% of the common stock based on the issuer’s reported share count and recent warrant exercises.
Additional Frazier Life Sciences vehicles report smaller positions, including 149,060 shares by Frazier Life Sciences X, L.P. (0.2%), 396,902 shares by Frazier Life Sciences XI, L.P. (0.6%), and 692,657 shares by Frazier Life Sciences XII, L.P. (1.0%). The funds also hold sizeable warrants and prefunded warrants that are subject to a 9.99% beneficial ownership cap. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Xilio.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Xilio Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
98422T100
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,676,472.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,676,472.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,676,472.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,676,472.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,676,472.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,676,472.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,676,472.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,676,472.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,676,472.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,060.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,060.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,060.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,060.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,060.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,060.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,060.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,060.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,060.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
396,902.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
396,902.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
396,902.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
396,902.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
396,902.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
396,902.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
396,902.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
396,902.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
396,902.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
Frazier Life Sciences XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
692,657.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
692,657.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
692,657.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
692,657.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
692,657.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
692,657.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
FHMLS XII, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
692,657.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
692,657.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
692,657.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,060.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,060.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,060.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
CUSIP No.
98422T100
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
149,060.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
149,060.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
149,060.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based on the sum of (i) 63,429,555 shares of the Issuer's Common Stock outstanding on December 19, 2025, as reported to the Reporting Persons by the Issuer and (ii) 5,915,091 shares of Common Stock that were subsequently purchased by the Reporting persons pursuant to the exercise of warrants to purchase shares of the Issuer's Common Stock.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Xilio Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
828 Winter Street, Suite 300, Waltham, MA, 02451.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron" and together with Topper, the "Members")
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
98422T100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 4,676,472 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.
FLS X directly holds 149,060 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 396,902 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.
FLS XII directly holds 692,657 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII.
The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain warrants and prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 37,494,128 shares of Common Stock, (ii) FLS X holds Warrants to purchase 1,195,108 shares of Common Stock, (iii) FLS XI holds Warrants to purchase 3,182,214 shares of Common Stock and (iv) FLS XII holds Warrants to purchase 5,553,459 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
02/13/2026
FHMLSP, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
02/13/2026
FHMLSP, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:
02/13/2026
Frazier Life Sciences X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
02/13/2026
FHMLS X, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
02/13/2026
FHMLS X, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:
02/13/2026
Frazier Life Sciences XI, L.P.
Signature:
Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
02/13/2026
FHMLS XI, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
02/13/2026
FHMLS XI, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:
02/13/2026
Frazier Life Sciences XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:
02/13/2026
FHMLS XII, L.P.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:
02/13/2026
FHMLS XII, L.L.C.
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, General Counsel of FHMLS XII, L.L.C.
Date:
02/13/2026
James N. Topper
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Date:
02/13/2026
Patrick J. Heron
Signature:
/s/ Jennifer Martin
Name/Title:
By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
What does the Schedule 13G/A filing reveal about Xilio Therapeutics (XLO) ownership?
The filing shows multiple Frazier Life Sciences funds collectively holding notable positions in Xilio Therapeutics common stock, led by Frazier Life Sciences Public Fund, L.P. with 4,676,472 shares, or 6.7% of the class, based on the issuer’s reported outstanding shares and warrant exercises.
How many Xilio Therapeutics (XLO) shares does Frazier Life Sciences Public Fund, L.P. hold?
Frazier Life Sciences Public Fund, L.P. directly holds 4,676,472 shares of Xilio Therapeutics common stock. This stake represents 6.7% of the outstanding common stock, calculated using 63,429,555 shares outstanding plus 5,915,091 shares purchased through warrant exercises as referenced in the filing.
Which other Frazier Life Sciences funds report Xilio Therapeutics (XLO) stakes?
Several affiliated funds report smaller Xilio positions: Frazier Life Sciences X, L.P. holds 149,060 shares (0.2%), Frazier Life Sciences XI, L.P. holds 396,902 shares (0.6%), and Frazier Life Sciences XII, L.P. holds 692,657 shares (1.0%), all in Xilio common stock, excluding related warrants.
What warrants related to Xilio Therapeutics (XLO) are disclosed in this Schedule 13G/A?
The filing notes warrants and prefunded warrants to buy Xilio common stock, including 37,494,128 shares for Frazier Life Sciences Public Fund, L.P. and additional warrants for FLS X, FLS XI, and FLS XII. Each warrant is exercisable only while keeping beneficial ownership below 9.99%.
How is the 6.7% ownership stake in Xilio Therapeutics (XLO) calculated in the filing?
The 6.7% figure is based on 63,429,555 Xilio common shares outstanding as of December 19, 2025, as reported to the Frazier entities, plus 5,915,091 common shares that were later purchased by them through warrant exercises, as described in the ownership footnotes.
Do the Frazier Life Sciences holders seek control of Xilio Therapeutics (XLO)?
The signatories certify that the Xilio securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. They also state the holdings are not part of any transaction intended to have that control-related purpose or effect.
